The drug discovery / product development phase has traditionally been the bottleneck that impedes innovation initiatives within life sciences companies. Patient stratification, outcome uncertainty, unintegrated data platforms, and compliance management are some of the pressing issues in the R&D domain. Startups operating in this space address these issues by combining their domain expertise and leveraging technology tenets such as analytics, cloud computing, and automation principles. In this report, starting with a long list of over 150 candidates, we shortlist 10 leading startups focused on disrupting drug discovery process. They are Atomwise, Bioz, DNAnexus, Emerald Therapeutics, GNS Healthcare, Phosphorus, SolveBio, Transcriptic, Vium, and Zymergen.
In this report, starting with a long list of over 150 candidates, we analyze 10 hot life sciences startups focused on disrupting drug discovery / product development. We focus on:
- Hot life sciences startups: key players driving disruption
- Funding scenario
- Key investors
- Leading investment areas
- Life sciences startups shortlist
- Startups leaderboard
- Implications for enterprises
- Implications for service providers
- Drug discovery / product development: Industry trends and startups
- Current status
- Innovation trends
- Changing the status quo
- Leading startups and profiles
- Business overview
- Leadership details
- Funding trail
- Disruption across technology & business
- Market buzz
The full report –Hot Drug Discovery / Product Development Startups:
Friends, Foes, and Frenemies in the Innovation Ecosystem – encompasses 20 hot life sciences startups across three investment areas – drug discovery / product development, clinical & pre-clinical trials, and sales & marketing.
Membership(s)
Healthcare & Life Sciences IT Outsourcing
